You are here: Home » 2022 » Archives for February 2022

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Butterfly Network, Inc. f/k/a Longview Acquisition Corp. Investors with Losses Exceeding $100K to Secure Counsel Before Important Deadline in Securities Class Action – BFLY

NEW YORK, Feb. 28, 2022 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Butterfly Network, Inc. f/k/a Longview Acquisition Corp. (NYSE: BFLY) (a) between February 16, 2021 and November 15, 2021, both dates inclusive (the "Class Period"), and/or (b) all holders of Butterfly common stock as of the record date for the special meeting of shareholders held on February 12, 2021 to consider approval of the merger between Longview and Butterfly (the "Merger") and entitled to vote on the Merger, of the important April 18, 2022 lead plaintiff deadline.

SO WHAT: If you purchased Butterfly securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Butterfly class action, go to https://rosenlegal.com/submit–form/?case_id=3602 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 18, 2022. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, the Proxy was negligently prepared and, as a result, contained untrue statements of material fact or omitted to state other facts necessary to make the statements made not misleading and were not prepared in accordance with the rules and regulations governing its preparation. Additionally, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and compliance policies. Specifically, the Proxy and defendants made false and/or misleading statements and/or failed to disclose that: (1) Butterfly had overstated its post–Merger business and financial prospects; (2) notwithstanding the ongoing COVID–19 pandemic, Butterfly's financial projections failed to take into account the pandemic's broad consequences, which included healthcare logistical challenges, and medical personnel fatigue; (3) accordingly, Butterfly's gross margin levels and revenue projections were less sustainable than the Company had represented; (4) all the foregoing was reasonably likely to have a material negative impact on Butterfly's business and financial condition; and (5) as a result, the Company's public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Butterfly action, go to https://rosenlegal.com/submit–form/?case_id=3602 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the–rosen–law–firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

———————————————–

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686–1060
Toll Free: (866) 767–3653
Fax: (212) 202–3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com


GLOBENEWSWIRE (Distribution ID 8492966)

Legit Security Announces Free Risk Assessment to Help Organizations Secure Themselves From Escalating Software Supply Chain Attacks

PALO ALTO, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) — Legit Security, a cyber security company with an enterprise SaaS platform to secure an organization's software supply chain, today announced a free Rapid Risk Assessment to help organizations proactively mitigate the risk of crippling software supply chain cyberattacks in the wake of Russia's invasion of Ukraine. The free risk assessment can provide organizations with immediate insight into vulnerabilities across their software supply chain environment as well as guidance on where to optimally place security resources and tools to mitigate future attacks. Qualifying organizations can obtain the free assessment at Legit Security's website: info.legitsecurity.com/rapid–risk–assessment.

Software supply chain attacks infiltrate an organization's internal software development supply chain and introduce vulnerabilities and backdoors within the organization's software, which are then passed on to unsuspecting customers making them vulnerable with a powerful and dangerous multiplier effect. Since the devastating SolarWinds attack in 2020, software supply chain attacks have increased 3x to 6x per year based on analysis from multiple government, industry and security vendor sources. The specter of further escalation of these attacks is anticipated in the wake of Russia's recent military invasion, including warnings to U.S. companies from government agencies such as the Cyber Security & Infrastructure Agency to "adopt a heightened posture when it comes to cybersecurity and protecting their most critical assets" and for companies to put their "shields up".

"Software supply chain cyberattacks can be extremely disruptive, and we want to help organizations become more resilient against these attacks," said Roni Fuchs, CEO of Legit Security. "Unfortunately, there's not enough best practice information and security tooling available freely in the market to help against this relatively new attack vector. After seeing the increase in frequency and severity of cyber–attacks related to Russia's invasion of Ukraine, we decided to step up and offer a free risk assessment to do our part to help."

The no–cost Rapid Risk Assessment uses Legit Security's SaaS–based security platform to conduct automated discovery and analysis of an organization's software supply chain environment to identify vulnerabilities, misconfigurations and security incidents. This automated scan analyzes the software delivery pipelines for gaps and leaks, the security posture of systems and infrastructure deployed within those pipelines, and the people and their security hygiene as they operate within it. Risk assessments are implemented in minutes via an agentless connection and the assessment is non–invasive with no changes or impact to existing development tools and workflows. Typical assessments take between a few minutes to two hours to complete, depending upon the environment size. More information on the full range of use cases available in the Legit Security platform and a list of Frequently Asked Questions are available on the company's website.

"Improving cyber defenses and staying alert to cyberattacks is now part of the business landscape, whether you are concerned about state–sponsored attacks, common cybercriminals or poor security hygiene," said Liav Caspi, Chief Technology Officer, Legit Security. "You can't protect what you can't see and unfortunately most organizations today do not have a handle on their own software supply chain environment. Regardless of an organization's current security maturity, we can help boost their awareness of current gaps and help them mitigate those risks much faster and easier than without an assessment. If every organization is more resilient to attacks, the chance of wide–ranging business and societal disruption goes down significantly."

For more information, visit legitsecurity.com.

About Legit Security
Legit Security protects software supply chains from attack by automatically discovering and securing the pipelines, infrastructure, code and people so that businesses can stay safe while releasing software fast. Legit provides an easy to implement SaaS platform that supports both cloud and on–premises resources and combines automated discovery and analysis capabilities with hundreds of security policies developed by industry experts with real–world SDLC security experience. This integrated platform keeps your software factory secure and provides continuous assurance that your applications are released without vulnerabilities.

Media Contact
Tony Keller
OutVox
tkeller@outvox.com


GLOBENEWSWIRE (Distribution ID 8493569)

NetSfere and HP Partner to Enable Secure Messaging and Collaboration Services for Healthcare Service Providers

CHICAGO, Feb. 28, 2022 (GLOBE NEWSWIRE) — NetSfere, a global provider of next–generation secure and compliant messaging and mobility solutions, has been named an authorized HP Independent Software Vendor (ISV) Program Partner to further the digitization of healthcare communication, streamline patient care and workflows, and curb the use of risky, non–compliant consumer–grade messaging apps.

"There is a critical need for secure, efficient communication in healthcare, especially as the pandemic has strained the time and resources of hospitals and medical staff," said Harsh Mamgain, NetSfere's VP of Product. "The vital work clinicians perform requires secure, compliant, and flexible messaging options that eliminate the need to turn to risky consumer–grade apps. By working with HP, NetSfere can now deliver the necessary secure and compliant collaboration solutions the industry needs to HP Healthcare's portfolio of clients as they digitize to streamline communications and continue to provide life–saving care to patients."

The pandemic accelerated the need for compliant, instantaneous communication tools to optimize clinical workflows, streamline staff communication, and make vital information readily accessible to authorized personnel across the healthcare industry. Replacing consumer–grade apps that pose crucial privacy and compliance risks and data–limited pagers, NetSfere Enterprise offers a HIPAA–compliant messaging platform that allows staff to safely communicate in real–time via a user–friendly web interface or mobile messaging app.

NetSfere's industry–leading secure messaging platform provides all preferred means of communication "" text, video, and voice "" in addition to emergency alert capabilities to present the most holistic, compliant, all–in–one communication solution for healthcare providers on the market. Created with end–to–end encryption and full IT control, the platform is compliant with global regulations and provides medical professionals with a private, highly secure and reliable, centrally managed and controlled, cloud–based messaging service.

The additional capabilities of NetSfere Lifeline allow personnel to send high priority, critical messaging to targeted teams or an entire organization to disperse emergency information in an attention–grabbing manner. Messages can include text, images, or locations, ensuring that all essential information is quickly shared in critical situations.

"HP Healthcare solutions are designed to help ensure safety, boost efficiency, and protect against security risks, making NetSfere's HIPAA–compliant platform an ideal fit as an ISV partner," said Cory McElroy, Vice President of Retail, and Industry Solutions at HP. "Healthcare is transforming rapidly, and this collaboration with NetSfere will fill a gap for providers as they implement other technology on HP Solutions."

For more information on NetSfere's portfolio of products, visit www.netsfere.com.

About NetSfere
NetSfere is a secure enterprise messaging service and platform from Infinite Convergence Solutions, Inc. NetSfere provides industry–leading security and message delivery capabilities, including global cloud–based service availability, device–to–device encryption, location–based features, and administrative controls. The service is also offered in partnership with Deutsche Telekom GmbH, one of the world's leading integrated telecommunications companies, and with NTT Ltd., a global information communications & technology service provider, to jointly offer NetSfere to its worldwide customers. The service leverages Infinite Convergence's experience in delivering mobility solutions to tier 1 mobile operators globally and technology that supports more than 500 million subscribers and over a trillion messages annually. NetSfere is also compliant with global regulatory requirements, including GDPR, HIPAA, Sarbanes–Oxley, ISO 27001, and others. Infinite Convergence Solutions has offices in the United States, Germany, India and Singapore. For more information, visit www.netsfere.com.

Media Contact
Erin Robertson Davila
Uproar PR for NetSfere
904–716–4439
erobertson@uproarpr.com


GLOBENEWSWIRE (Distribution ID 8493001)

CS Global Partners: Bitcoin Heaven El Salvador Newest Nation to Consider Citizenship by Investment 

LONDON, Feb. 28, 2022 (GLOBE NEWSWIRE) — Salvadorian President Nayib Bukele on Sunday said he will send Congress a proposal to grant citizenship to foreigners who invest in the Central American country, another step in the populist leader's plan to bolster the country's economy by attracting non–traditional capital.

"I'm sending 52 legal reforms to congress to remove red tape, reduce bureaucracy, create tax incentives, citizenship, in exchange for investments, new securities laws, stability contracts, etc.," Bukele said on Twitter.

Since September, El Salvador has attracted increasing international interest when it passed a law that made the cryptocurrency Bitcoin legal tender. Like the new package of El Salvador reforms, that law was first proposed by Bukele.

If the new citizenship legal reform is passed, El Salvador would become one of the few countries to offer a citizenship by investment programme, joining several other small countries, mainly in the Caribbean, according to the world's leading government advisory and marketing firm CS Global Partners.

CBI Programmes usually require a vetted applicant to make a minimum monetary contribution to a government fund or purchase real estate in the country to obtain citizenship.

Greater crypto freedom with CBI

"An increasing number of crypto investors and tech entrepreneurs have started looking to second citizenship as a means of achieving greater freedom", says Micha Emmett, the CEO of CS Global Partners. She added that this growing demographic has combined assets like cryptocurrency with additional citizenships to unlock financial autonomy and wealth diversity.

"As crypto gained more traction in the last few years, we've started seeing an increase in interest for second citizenship from the tech community. This demographic, technologically, is already global, so it makes sense that they want their assets to reflect this mindset," she said.

A second citizenship offers a level of safety and security that investors can rely on during political or economic turmoil. The onset of the COVID–19 pandemic has particularly triggered families to obtain second citizenship to better protect themselves and their financial assets whilst increasing their global mobility.

The dual–island nation of St Kitts and Nevis has been a popular destination amongst the wealthy, mainly because of"its CBI Programme. This initiative provides a trusted route to second citizenship once an applicant invests in the nation. Established in 1984, St Kitts and Nevis' programme is internationally recognised as a "Platinum Standard' brand.

Despite being the smallest sovereign state in the Western Hemisphere, St Kitts and Nevis is one of the most technologically advanced nations in the region regarding its crypto–friendly approach to banking. The islands recently passed a bill simplifying the trade of virtual assets and are also currently running a digital currency pilot programme known as DCash. St Kitts and Nevis also does not impose income, inheritance, or capital gains tax, allowing citizens to breathe a little freer as they focus on the investments that matter to them.

More countries are considering the CBI route

El Salvador is not the only country tossing with the idea of citizenship by investment to boost its economy. Just last month, Pakistan's Information Minister Fawad Chaudhry said that the Government would offer Pakistani nationality to foreign investors, particularly as a way to recruit heavy investments from the wealthy individuals of neighbouring China and Pakistan.

Jamaica's Government is also being pushed to consider adopting a citizenship by investment programme with the funds gained through the process used for various development projects.

Julian Dixon, CEO and broker at Jamaica Sotheby's International Realty, made the call in October 2021. She said funds gained from the project should be used to invest in the country's infrastructure, real estate, job creation and business development.

"For a number of countries, especially in the Caribbean, there is no denying that CBI programmes offer a much–needed injection of foreign direct investment, often in a way that can make a significant developmental difference. These funds are channelled into reducing international aid and debt, developing the tourism sector, job growth as foreigners often employ locals when expanding offices or constructing properties, and sustainability initiatives," CS Global Partner's Emmett commented.

Dixon particularly pointed out that St Kitts and Nevis, which pioneered the citizenship by investment programme close to four decades ago and has invested upwards of US$300 million from the programme in modernising its infrastructure. She said Jamaica could do the same.

A trusted product

St Kitts and Nevis offers a trusted product that has been acclaimed globally by independent studies like the annual"CBI Index"published by the Financial Times' PWM magazine. With an influx of citizenship programmes on the market, St Kitts and Nevis continues to be a powerhouse within the industry with one of the longest–standing programmes in operation.

Those who become citizens gain a wealth of benefits, including increased global mobility to financial centres in Asia, Europe and Africa, alternative business prospects, and the ability to pass citizenship down, thus establishing a future legacy for one's family. Additionally, St Kitts and Nevis does not impose any personal income, gift or inheritance tax and has a currency pegged to the US dollar, making it a financially lucrative destination for savvy investors.

The country's CBI Unit, which processes all economic citizenship applications, usually issues approvals or denials within a period of three months. There are no interviews, language, education, or business requirements.

Travel to the island is not obligatory, and no minimum residence stays apply either before or after Citizenship is obtained. Due diligence"procedures remain among the industry's most robust, and the nation is strengthening them by focusing on enhancing fingerprinting and biometrics.

For those looking to hedge against future risks, combining the dual–island nation's crypto–friendly policies and second citizenship provides investors with the ultimate insurance policy during times of unpredictability. St Kitts and Nevis remains the best destination for securing your future with a thriving financial services sector and a growing crypto hub.

Contact: pr@csglobalpartners.com, www.csglobalpartners.com / +447824029952


GLOBENEWSWIRE (Distribution ID 8492969)

ROSEN, GLOBALLY RECOGNIZED INVESTOR COUNSEL, Encourages Acutus Medical, Inc. Investors with Losses Over $100K to Secure Counsel Before Important Deadline in Securities Class Action – AFIB

NEW YORK, Feb. 26, 2022 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Acutus Medical, Inc. (NASDAQ: AFIB) between May 13, 2021 and November 11, 2021, inclusive (the "Class Period") of the important April 18, 2022 lead plaintiff deadline.

SO WHAT: If you purchased Acutus Medical securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Acutus Medical class action, go to https://rosenlegal.com/submit–form/?case_id=3255 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 18, 2022. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) a material percentage of the AcQMap systems under evaluation had been randomly installed at sites with little, if any, consideration given to whether the healthcare providers at the selected locations were likely to adopt, or desire, Acutus Medical's products; (2) a material percentage of the AcQMap systems under evaluation had been installed in locations where Acutus Medical did not possess the infrastructure necessary to appropriately educate, train, and support medical service providers on the system's operations; (3) as a result, Acutus Medical was in the process of designing a strategic plan to terminate and relocate approximately 20% of then–existing AcQMap systems evaluation arrangements; (4) Acutus Medical's management discussion and analysis was materially false and misleading and failed to disclose that the termination and relocation of approximately 20% of existing AcQMap systems evaluation arrangements was reasonably likely to have a material adverse effect on Acutus Medical's 2021 financial results; and (5) Acutus Medical's risk factor discussions were materially false and misleading and made reference to potential risks without disclosing that such risks were then–existing or adequately describing the specific nature of the risks then facing Acutus Medical. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Acutus Medical class action, go to https://rosenlegal.com/submit–form/?case_id=3255 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the–rosen–law–firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

———————————————–

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686–1060
Toll Free: (866) 767–3653
Fax: (212) 202–3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com


GLOBENEWSWIRE (Distribution ID 8492870)

ROSEN, A TOP RANKED LAW FIRM, Encourages Fennec Pharmaceuticals Inc. Investors with Losses Over $100K to Secure Counsel Before Important Deadline in Securities Class Action – FENC

NEW YORK, Feb. 26, 2022 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Fennec Pharmaceuticals Inc. (NASDAQ: FENC) between May 28, 2021 and November 26, 2021, inclusive (the "Class Period") of the important April 11, 2022 lead plaintiff deadline.

SO WHAT: If you purchased Fennec Pharmaceuticals securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Fennec Pharmaceuticals class action, go https://rosenlegal.com/submit–form/?case_id=3153 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 11, 2022. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Fennec Pharmaceuticals had not successfully remediated, and overstated its efforts to remediate, issues with the manufacturing facility of its drug product manufacturer for PEDMARK; (2) as a result, the U.S. Food and Drug Administration was unlikely to approve the Resubmitted PEDMARK New Drug Application ("NDA"); (3) accordingly, the regulatory and commercial prospects of the Resubmitted NDA were overstated; and (4) as a result, the Company's public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Fennec Pharmaceuticals class action, go https://rosenlegal.com/submit–form/?case_id=3153 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the–rosen–law–firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686–1060
Toll Free: (866) 767–3653
Fax: (212) 202–3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com


GLOBENEWSWIRE (Distribution ID 8492844)

Chinmay J. Upadhyat becomes Regional Vice President, South Asia for Nikkiso Clean Energy & Industrial Gases Group

TEMECULA, Calif., Feb. 24, 2022 (GLOBE NEWSWIRE) — Nikkiso Cryogenic Industries' Clean Energy & Industrial Gases Group ("Group"), a part of the Nikkiso Co., Ltd (Japan) group of companies, announces that Chinmay J. Upadhyat has joined the Group as Regional Vice President, South Asia region.

Chinmay will be based in Nikkiso Cosmodyne India Private Ltd, their large manufacturing and competence center in Gujarat India.

This important addition to their management team is the result of growth in the market environment and is in line with the objectives of the Industrial Division of Nikkiso to better serve and support their customers in the Southern Asia Market.

Chinmay started his career in 1995 as a Production Engineer with Anup Engineering and Inductotherm India, then served as key account manager for ten years with Dresser Rand India. Since 2008 he has been Regional then Assistant General Manager for Burckhardt Compression India where he was responsible for sales and business development of new machines for the Indian market.

With his broad experience in the CNG, LNG, H2 and industrial gas markets in India, Chinmay will lead the Nikkiso Clean Energy & Industrial Gases sales and service teams in this important region and embark on a mission to deliver market share growth in a sustainable and profitable way.

"Chinmay will be a perfect addition to our management team with his proficiency in business development, equipment, service, aftermarket sales and market knowledge," according to Emile Bado, Vice President, Sales & Business Development of the Group.

Chinmay has a Mechanical Engineering degree from Government Polytechnic, Ahmedabad, a Bachelor's in Technology from JNRVD University, Rajasthan and an MBA from Sikkim Manipal University in Manipal.

ABOUT CRYOGENIC INDUSTRIES
Cryogenic Industries, Inc. (now a member of Nikkiso Co., Ltd.) member companies manufacture engineered cryogenic gas processing equipment and small–scale process plants for the liquefied natural gas (LNG), well services and industrial gas industries. Founded over 50 years ago, Cryogenic Industries is the parent company of ACD, Cosmodyne and Cryoquip and a commonly controlled group of approximately 20 operating entities.

For more information please visit www.cryoind.com and www.nikkiso.com.

MEDIA CONTACT:
Anna Quigley
+1.951.383.3314
aquigley@cryoind.com


GLOBENEWSWIRE (Distribution ID 8491872)

Provation appoints Gulf Medical Company as exclusive partner in Saudi Arabia for its market-leading clinical productivity solution

Jeddah, Saudi Arabia, and Minneapolis, Minn., USA, Feb. 24, 2022 (GLOBE NEWSWIRE) — Provation, the premier software provider of procedure documentation and clinical decision support solutions, today announced an exclusive partnership with Gulf Medical Company, Ltd., a market leader in medical device and software distribution. The partnership agreement allows Gulf Medical to sell and distribute the global Gold Standard of gastroenterology (GI) and respiratory procedure documentation software, Provation MD, throughout the Kingdom of Saudi Arabia (KSA).

For more than 25 years, Provation has been a market leader in clinical productivity software. Every day, more than 15,000 physicians and endoscopists in over 5,000 healthcare facilities worldwide use its intuitive workflows, image capture, and deep medical content for gastroenterology and respiratory documentation. Provation MD integrates with existing hospital information systems to replace paper clinical documentation, while improving the consistency, accuracy, and efficiency of procedure notes.

"Gulf Medical looks to its partnership with Provation as a milestone in our diversification into the healthcare IT business stream, which aligns with the Saudi government's 2030 vision for digitization and Gulf Medical's vision in bringing the most innovative solutions to the Middle East since 1983," said Mohamed A. Raouf, Director of Services and New Technologies at Gulf Medical. "As a market leader in its domain, Provation can shift our customers' experience into a new era of facilitating electronic documentation and reporting and GI workflow management."

Provation awarded the partnership to Gulf Medical because of its excellent reputation and strong customer relationships with both the private and public hospital sectors throughout the region.

"We are very excited to have Gulf Medical as the exclusive distributor of Provation MD in Saudi Arabia," said Daniel Hamburger, CEO of Provation. "The Gulf Medical team knows the medical device and software needs of healthcare organizations in their region. This partnership will allow us to further expand Provation's presence throughout the Kingdom, while empowering more clinicians and endoscopists with the tools they need to deliver quality healthcare for all."

Gulf Medical plans to rapidly introduce Provation MD to leading healthcare facilities across the Kingdom of Saudi Arabia (KSA).

About Provation

Provation is a leading provider of healthcare software and SaaS solutions for clinical procedure reports, anaesthesia documentation, quality reporting, and more. Provation is best known globally for providing the Gold Standard for gastroenterology (GI) procedure documentation, Provation MD, and #1 Best in KLAS anaesthesia information management system, Provation iPro. Our purpose is to empower providers worldwide with the tools they need to deliver quality healthcare for all.

Provation serves more than 5,000 hospitals and health systems, surgery centres, and medical offices, and 700 physician groups worldwide. In 2021, Provation was acquired by Fortive Corporation, a Fortune 1000 company that builds essential technology and accelerates transformation in high–impact fields like workplace safety, engineering, and healthcare. For more information about our solutions, visit provationmedical.com.

About Gulf Medical Company, LTD

Gulf Medical Co. was founded in 1983 to bring the most innovative medical solutions to the Middle East. It is owned by Al–Naghi Group (since 1911) and it serves the medical field in different product lines, bringing many firsts in medical solutions to the region; with a core value that its service does not end at the award of a sale; but only begins at the award and continues for many years to come after, this is side by side to customers and patients. Learn more at www.gulfmedical.com.

Attachment


GLOBENEWSWIRE (Distribution ID 8491023)

Standard Lithium and Lanxess Finalize Plan for First Commercial Lithium Project in Arkansas

VANCOUVER, British Columbia, Feb. 24, 2022 (GLOBE NEWSWIRE) — Standard Lithium Ltd. ("Standard Lithium" or the "Company") (TSXV: SLI) (NYSE.A: SLI) (FRA: S5L), an innovative technology and lithium project development company, has reached an agreement (the "Agreement"), dated February 23, 2022, with its strategic partner, LANXESS Corporation ("Lanxess"), that streamlines and expedites the plan for development of the first commercial lithium project in Arkansas, which is to be constructed at an operational Lanxess facility in El Dorado, Arkansas (the "Project"). Under the Agreement, Standard Lithium will control all development of the Project leading up to and including the completion of the Front End Engineering Design ("FEED") study. Standard Lithium will hold, at a minimum, a 51% majority equity stake in the Project and may retain as much as 100% of the Project. The Company will also retain 100% ownership of its South West Arkansas Project, all its proprietary extraction technologies, relevant intellectual property and know–how.

Robert Mintak, CEO of Standard Lithium commented, "This agreement builds upon the successful working relationship that has been established between the companies. By entering into this Agreement, Standard Lithium takes ownership of the Project and its development timelines with a clear path towards delivering the first new commercial lithium production in the USA in over 50 years.1 We have already begun the process of engaging and integrating the strategic team members to make this project a success. With the recent investment from our largest shareholder, Koch Strategic Platforms, we are fully funded to complete all planned Project milestones leading to a Definitive Feasibility Study, which is expected to be completed in Q4 2022".

Key Highlights:

  • Standard Lithium will form an initially wholly–owned company ("Project Company") that owns 100% of the Project during pre–FEED and FEED engineering studies (see news release dated January 20th, 2022). The FEED engineering will be used to produce a NI43–101 Definitive Feasibility Study ("DFS") in Q4 2022;
  • Lanxess will, via a series of commercial agreements, provide the brine supply for the Project, the Project site lease, and rights of way, infrastructure, and other services for the Project;
  • Standard Lithium will provide a market fee–based license to the Project Company of its suite of intellectual property;
  • Standard Lithium is able to utilize its intellectual property, extraction technology and know–how at its 100% owned South West Arkansas Project, certain other sites in Arkansas and at all project sites outside of Arkansas, and will maintain control and ownership over the future development of its IP portfolio; and,
  • Lanxess is obliged to support development of the Project and upon completion of a DFS, has the option to acquire an equity interest in the Project Company of up to 49% and not less than 30%, at a price equal to a ratable share of SLL's aggregate investment in the Project Company.

If Lanxess acquires an ownership interest:

  • The parties will share the costs of financing construction of the Project on a ratable basis; and,
  • Lanxess will have the right to acquire some, or all of the lithium carbonate off–take produced at the commercial plant at market–based terms less a handling fee.

If Lanxess does not acquire an ownership interest:

  • Standard Lithium will own 100% of the Project including customary dividends, distribution, or similar rights;
  • Standard Lithium can elicit bids from other interested parties to buy up to 49% of the Project Company; and,
  • Lanxess will have the right to acquire some, or all of the lithium carbonate off–take produced at the commercial plant at a price of market minus up to 20%, to be agreed by Lanxess and Standard Lithium and taking into consideration several key commercial agreements (including the costs of brine supply and disposal for the Project, the Project site lease cost and rights of way, infrastructure, and other services for the Project).

The parties have also agreed that development of the second and third projects on the Lanxess properties will be on a joint basis and that the parties will perform the same roles using similar contractual structures as the first Project. Lanxess will also have the right to purchase the lithium carbonate off–take from the additional projects upon market–based terms to be agreed by Lanxess and Standard Lithium, taking into consideration other commercial agreements required for their development (e.g. site leases, brine supply/disposal etc.).

Advisors
Stifel Nicolas Canada Inc. acted as financial advisor to Standard Lithium during negotiation of this Agreement.

About Standard Lithium Ltd.
Standard Lithium is an innovative technology and lithium development company. The Company's flagship project is located in southern Arkansas, where it is engaged in the testing and proving of the commercial viability of lithium extraction from over 150,000 acres of permitted brine operations. The Company operates its first–of–a–kind industrial–scale direct lithium extraction demonstration plant at Lanxess's south plant facility in southern Arkansas. The demonstration plant utilizes the Company's proprietary LiSTR technology to selectively extract lithium from Lanxess's tail brine. The demonstration plant is being used for proof–of–concept and commercial feasibility studies. The scalable, environmentally friendly process eliminates the use of evaporation ponds, reduces processing time from months to hours and greatly increases the effective recovery of lithium. The Company is also pursuing the resource development of over 30,000 acres of separate brine leases located in southwest Arkansas, referred to as the South West Arkansas Lithium Project, and approximately 45,000 acres of mineral leases located in the Mojave Desert in San Bernardino County, California.

Standard Lithium is jointly listed on the TSX Venture Exchange and the NYSE American under the trading symbol "SLI"; and on the Frankfurt Stock Exchange under the symbol "S5L". Please visit the Company's website at http://www.standardlithium.com.

On behalf of the Board of Standard Lithium Ltd.
Robert Mintak, CEO & Director

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release may contain certain "Forward–Looking Statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995 and applicable Canadian securities laws. When used in this news release, the words "anticipate", "believe", "estimate", "expect", "target, "plan", "forecast", "may", "schedule" and other similar words or expressions identify forward–looking statements or information. These forward–looking statements or information may relate to expected development of the Project and future phases, the timeline for completion of the DFS, negotiation of definitive documentation with Lanxess, accuracy of mineral or resource exploration activity, reserves or resources, regulatory or government requirements or approvals, the reliability of third party information, continued access to mineral properties or infrastructure, fluctuations in the market for lithium and its derivatives, changes in exploration costs and government regulation in Canada and the United States, and other factors or information. Such statements represent the Company's current views with respect to future events and are necessarily based upon a number of assumptions and estimates that, while considered reasonable by the Company, are inherently subject to significant business, economic, competitive, political and social risks, contingencies and uncertainties. Many factors, both known and unknown, could cause results, performance or achievements to be materially different from the results, performance or achievements that are or may be expressed or implied by such forward–looking statements. The Company does not intend, and does not assume any obligation, to update these forward–looking statements or information to reflect changes in assumptions or changes in circumstances or any other events affections such statements and information other than as required by applicable laws, rules and regulations.

1 See https://pubs.usgs.gov/periodicals/mcs2021/mcs2021–lithium.pdf


GLOBENEWSWIRE (Distribution ID 8491422)

Dante Labs selected as Genetic Tests provider for Abu Dhabi Executive Office Employee’s Wellbeing Week

NEW YORK, Feb. 23, 2022 (GLOBE NEWSWIRE) — Dante Labs, a global leader in genomics and precision medicine, is pleased to announce that the company has been selected as a genetic services provider for Abu Dhabi Executive Office (ADEO) employees for their wellbeing week.

Beginning on February 14, 2022, Dante will be providing whole genome sequencing to ADEO employees as part of the company's benefit package for all employees.

The testing will be run in the new Dante Dubai laboratory and will provide employees with invaluable insights about their wellness and longevity, including risk of developing certain health conditions, evidence of intolerances to food, and indications for a personalized and balanced diet and fitness training.

"We are very proud to be increasing access to genomic sequencing through this great opportunity to provide our service to ADEO employees. It is through employee testing like this that we are able to deliver invaluable health insights to more people and ultimately better healthcare and longevity," said Andrea Riposati, CEO of Dante Labs. "The UAE is clearly becoming a global leader in genomics, and we are thrilled to have invested in this amazing country."

"Not only is this extremely exciting, but we are hopeful that testing programs such as these will pave the way to wider adoption of genomics in other fields such as R&D, training and development programs," said Prof. Mattia Capulli, Chief Scientific Officer of Dante Labs.

"The Abu Dhabi Executive Office is extremely happy and appreciates Dante Labs for their great service that contributes to our employee's wellbeing by providing the unique actionable benefit from genomics in both clinical and consumer settings from sports to nutrigenomics," said Dr. Fatima Al Kaabi, Director of Genome Office, Abu Dhabi Executive Office.

About Dante Labs

Dante Labs is a global genomic data company building and commercializing a new class of transformative health and longevity applications based on whole genome sequencing and AI. Our assets include one of the largest private genome databases with research consent, a proprietary software platform designed to unleash the power of genomic data at scale and proprietary processes which enable an industrial approach to genomic sequencing.

Contact

Laura D'Angelo
VP of Investor Relations
ir@dantelabs.com
+39 0862 191 0671
www.dantelabs.com

A photo accompanying this announcement is available at: https://www.globenewswire.com/NewsRoom/AttachmentNg/95013cb8–6b11–4222–ab49–476331c160f3


GLOBENEWSWIRE (Distribution ID 8491143)